- Home
- DSL vs ELVN Comparison
DSL vs ELVN Comparison
Compare DSL & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSL
- ELVN
- Stock Information
- Founded
- DSL 2013
- ELVN 2016
- Country
- DSL United States
- ELVN United States
- Employees
- DSL N/A
- ELVN N/A
- Industry
- DSL Trusts Except Educational Religious and Charitable
- ELVN Biotechnology: Pharmaceutical Preparations
- Sector
- DSL Finance
- ELVN Health Care
- Exchange
- DSL Nasdaq
- ELVN Nasdaq
- Market Cap
- DSL 1.4B
- ELVN 1.2B
- IPO Year
- DSL N/A
- ELVN 2020
- Fundamental
- Price
- DSL $11.70
- ELVN $21.35
- Analyst Decision
- DSL
- ELVN Strong Buy
- Analyst Count
- DSL 0
- ELVN 5
- Target Price
- DSL N/A
- ELVN $41.20
- AVG Volume (30 Days)
- DSL 551.0K
- ELVN 421.5K
- Earning Date
- DSL 01-01-0001
- ELVN 11-12-2025
- Dividend Yield
- DSL 11.30%
- ELVN N/A
- EPS Growth
- DSL N/A
- ELVN N/A
- EPS
- DSL N/A
- ELVN N/A
- Revenue
- DSL N/A
- ELVN N/A
- Revenue This Year
- DSL N/A
- ELVN N/A
- Revenue Next Year
- DSL N/A
- ELVN $20.05
- P/E Ratio
- DSL N/A
- ELVN N/A
- Revenue Growth
- DSL N/A
- ELVN N/A
- 52 Week Low
- DSL $10.58
- ELVN $13.30
- 52 Week High
- DSL $13.00
- ELVN $30.03
- Technical
- Relative Strength Index (RSI)
- DSL 21.05
- ELVN 57.25
- Support Level
- DSL $12.02
- ELVN $19.98
- Resistance Level
- DSL $12.34
- ELVN $22.42
- Average True Range (ATR)
- DSL 0.13
- ELVN 0.95
- MACD
- DSL -0.06
- ELVN 0.17
- Stochastic Oscillator
- DSL 9.27
- ELVN 71.20
About DSL DoubleLine Income Solutions Fund of Beneficial Interests
DoubleLine Income Solutions Fund is a closed-end management investment company. Its primary investment objective is to seek high income and its secondary objective is to seek capital appreciation. It invests in debt securities and other income-producing investments anywhere in the world, including emerging markets. The company's investment portfolio comprises foreign corporate bonds, U.S. corporate bonds, bank loans, collateralized loan obligations, non-agency commercial mortgage backed obligations, asset-backed obligations, and municipal bonds among others.
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.